Targeting KRAS G12D: Advances in Inhibitor Design

Area of Science:

• Oncology
• Drug Discovery
• Molecular Biology

Background:

• The KRAS G12D mutation is a key driver in pancreatic cancer, colorectal cancer, and non-small cell lung cancer.
• This mutation is considered "undruggable" due to its lack of a reactive site, leading to PI3K/AKT pathway activation and an immunosuppressive tumor microenvironment.

Purpose of the Study:

• To review recent advancements in therapeutic strategies targeting the KRAS G12D mutation.
• To discuss novel inhibitor designs, clinical trial progress, and challenges in overcoming resistance.

Main Methods:

• Summary of small-molecule inhibitors, including non-covalent and covalent approaches.
• Exploration of alternative modalities like Proteolysis Targeting Chimeras (PROTACs), peptide inhibitors, and monobodies.
• Evaluation of clinical trial data and discussion of resistance mechanisms.

Main Results:

• Development of highly selective non-covalent inhibitors (e.g., MRTX1133) using ionic interactions.
• Emergence of novel covalent strategies like strain-release alkylation and tri-complex inhibitors (e.g., RMC-9805).
• Progress in clinical trials for KRAS G12D-targeted therapies.

Conclusions:

• Significant progress in developing druggable KRAS G12D inhibitors is reshaping cancer therapy.
• Future directions include optimizing drug delivery and combination therapies to improve efficacy and durability.
• Addressing acquired resistance is crucial for long-term clinical success.